Skip to main content

Table 1 Baseline and treatment characteristics

From: Mode of progression after radioembolization in patients with colorectal cancer liver metastases

Characteristic N (%) or median with range   
90Y-resin 90Y-glass 166Ho No extrahepatic disease Extrahepatic disease at baseline Total
N 46 (51) 20 (22) 24 (27) 48 (53) 42 (47) 90 (100)
Age (years) 65 (35–84) 67 (45–78) 66 (40–84) 66 (34–84) 66 (40–84) 66 (35–84)
Gender       
 Male 33 (72) 15 (75) 17 (63) 34 (71) 31 (74) 65 (72)
 Female 13 (28) 5 (25) 7 (37) 14 (29) 11 (26) 25 (28)
WHO performance status       
 0 24 (52) 15 (75) 19 (79) 29 (60) 29 (69) 58 (64)
 1 19 (41) 5 (25) 5 (21) 18 (38) 11 (26) 29 (32)
 2 3 (7) 0 (0) 0 (0) 1 (2) 2 (5) 3 (4)
Previous chemotherapy lines       
 0 1 (2) 0 (0) 0 (0) 1 (2) 0 (0) 1 (1)
 1 13 (28) 9 (45) 11 (46) 18 (38) 15 (36) 33 (37)
 2 21 (46) 8 (40) 11 (46) 21 (44) 9 (21) 40 (44)
 3 11 (24) 3 (15) 2 (8) 8 (17) 8 (19) 16 (18)
Bevacizumab 29 (63) 13 (65) 13 (54) 32 (67) 23 (55) 55 (61)
Capecitabine 42 (91) 18 (90) 20 (83) 41 (85) 39 (93) 80 (89)
Cetuximab 2 (4) 0 (0) 1 (4) 1 (2) 2 (5) 3 (4)
Cisplatin 1 (2) 0 (0) 0 (0) 1 (2) 0 (0) 1 (1)
Erlotinib 0 (0) 0 (0) 1 (4) 0 (0) 1 (2) 1 (1)
Irinotecan 26 (57) 9 (45) 10 (42) 23 (48) 22 (52) 45 (50)
Oxaliplatin 40 (87) 17 (85) 23 (96) 41 (85) 39 (93) 80 (89)
Paclitaxel 0 (0) 0 (0) 1 (4) 0 (0) 1 (1) 1 (1)
Panitumumab 8 (17) 4 (20) 3 (13) 9 (19) 6 (14) 15 (17)
5-FU 7 (15) 3 (15) 5 (21) 7 (15) 8 (19) 15 (17)
Previous locoregional treatment       
 Yes 17 (37) 7 (35) 6 (25) 17 (35) 13 (31) 30 (33)
 No 29 (63) 13 (65) 18 (75) 31 (65) 29 (69) 60 (67)
Metastasis pattern       
 Synchronous 31 (67) 15 (75) 15 (63) 27 (56) 34 (81) 61 (68)
 Metachronous 15 (33) 5 (25) 9 (37) 21 (44) 8 (19) 29 (32)
Time since diagnosis (months) 25 (3–97) 24 (11–110) 26 (6–92) 26 (3–110) 21 (5–92) 25 (3–110)
Time since diagnosis of metastatic disease (months) 17 (3–72) 23 (2–50) 18 (2–92) 17 (2–54) 21 (5–92) 19 (2–92)
KRAS status       
 Wild-type 16 (35) 8 (40) 9 (37) 21 (44) 12 (29) 33 (37)
 Mutation 11 (24) 3 (15) 6 (26) 7 (15) 13 (31) 20 (22)
 Unknown 19 (41) 9 (45) 9 (37) 10 (21) 17 (40) 37 (41)
CEA level 72 (3–2700) 68 (3–640) 100 (2–6000) 61 (2–2700) 115 (3–6000) 88 (2–6000)
 Unknown 12 (26) 4 (20) 1 (4) 7 (15) 10 (24) 17 (19)
Primary tumor in situ       
 Yes 1 (2) 4 (20) 2 (8) 2 (4) 5 (12) 7 (8)
 No 45 (98) 16 (80) 22 (92) 46 (96) 37 (88) 83 (92)
Extrahepatic disease (all metastases)       
 None 27 (59) 9 (45) 10 (42) 48 (100) 0 (0) 48 (53)
 Lymph node metastases 12 (26) 8 (40) 7 (29) - 25 (60) 25 (28)
 Lung metastases 8 (17) 2 (10) 7 (29) - 17 (40) 17 (19)
 Abdominal wall metastases 1 (2) 0 (0) 0 (0) - 1 (2) 1 (1)
 Spleen metastases 0 (0) 0 (0) 2 (8) - 1 (2) 1 (1)
 Adrenal gland metastases 0 (0) 2 (10) 0 (0) - 2 (5) 2 (2)
 Peritoneal metastases 1 (2) 0 (0) 2 (8) - 3 (7) 3 (3)
Type of radioembolization       
 Whole-liver 41 (89) 12 (60) 20 (83) 38 (79) 35 (83) 73 (81)
 Lobar 5 (11) 8 (40) 4 (17) 10 (21) 7 (17) 17 (19)
Injected activity (MBq) 1526 (636–2320) 2037 (711–6277) 6565 (2213–11,627) 1882 (636–11,164) 1992 (680–11,627) Not applicable
Lungshunt (%) 5 (0.1–17) 2.3 (1–26) 4.6 (0.3–16) 4.5 (0.1–17) 3.4 (0.8–26) 4 (0.1–26)
  1. This table shows the baseline characteristics for the 90 included patients